

### **Supplemental information**

#### Characterization of the fatty acid metabolism

#### in colorectal cancer to guide clinical therapy

Chengsheng Ding, Zezhi Shan, Mengcheng Li, Hongqi Chen, Xinxiang Li, and Zhiming Jin



## Figure S1. Comparison between colorectal cancer tissue and normal tissue samples in the TCGA cohort.

**A.** The heat map of 70 differentially expressed fatty acid metabolism-related genes. **B.** The result of GO enrichment analysis of differentially expressed fatty acid metabolism-related genes. **C.** The result of KEGG enrichment analysis of differentially expressed fatty acid metabolism-related genes.



# Figure S2. The relationship between risk scores and survival status of samples in the training set and validation set.

**A-C.** In the training set. **D-F.** In the validation set. **A** and **D**. Distribution of risk scores ranked from low to high. **B** and **E**. Comparison of survival status between low- and high- risk score groups. **C** and **F**. Heat map of 8 genes selected by LASSO Cox regression analysis.



#### Figure S3. Construction of fatty acid metabolism score model.

**A.** The fatty acid metabolism score difference between high risk score and low risk score groups. **B.** The relationship between risk score model and fatty acid metabolism score. **C.** Survival analysis for subgroup patients stratified by fatty acid metabolism score. **D.** The predictive value of fatty acid metabolism score in CRC patients. AUC, 0.652.





## Figure S4. Characteristics of immune-checkpoint related gene and known signatures in patients with high risk score and low risk score.

**A.** Correlation between TME infiltration cells and fatty acid metabolism genes associated with prognosis. **B-D.** The immunity- checkpoint related gene expression difference in high score group and low score group. **E.** The risk score difference in CMS subtypes. **F.** Heat map showed known signatures genes expression in risk score model.

MICA

FC

High

Low

A





**A.** PPI network of DEGs between low- and high- risk score groups. **B-J.** Survival analysis for patients with high or low ACTC1 (B), CDH2 (C), EGF (D), FN1(D), GNG8 (E), KRT5 (F), KRT14 (G), CDKN2A (H), SERPINE1 (I) as well as SYP (J).

А